GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Cash Ratio

Hansoh Pharmaceutical Group Co (HKSE:03692) Cash Ratio : 3.17 (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Hansoh Pharmaceutical Group Co's Cash Ratio for the quarter that ended in Jun. 2023 was 3.17.

Hansoh Pharmaceutical Group Co has a Cash Ratio of 3.17. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Cash Ratio or its related term are showing as below:

HKSE:03692' s Cash Ratio Range Over the Past 10 Years
Min: 0.74   Med: 3.57   Max: 8.25
Current: 3.62

During the past 8 years, Hansoh Pharmaceutical Group Co's highest Cash Ratio was 8.25. The lowest was 0.74. And the median was 3.57.

HKSE:03692's Cash Ratio is ranked better than
88.8% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs HKSE:03692: 3.62

Hansoh Pharmaceutical Group Co Cash Ratio Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Cash Ratio Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial 2.34 5.10 6.26 8.25 3.62

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.26 6.53 8.25 3.17 3.62

Competitive Comparison of Hansoh Pharmaceutical Group Co's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's Cash Ratio falls into.



Hansoh Pharmaceutical Group Co Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Hansoh Pharmaceutical Group Co's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=24147.227/2925.236
=8.25

Hansoh Pharmaceutical Group Co's Cash Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash Ratio (Q: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=25743.453/8111.386
=3.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hansoh Pharmaceutical Group Co  (HKSE:03692) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Hansoh Pharmaceutical Group Co Cash Ratio Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines